IDEAYA Biosciences, Inc. (IDYA): Shareholders' Equity
$1.02B
As of 2025-12-31
$1.20B
As of 2026-06-30
+43.0%
3-year compound annual growth
+38.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.02B | -3.4% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $1.06B | +70.5% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $621.09M | +77.7% | 2026-02-17, Balance as of period end |
| 2022-12-31 | $349.45M | +15.9% | 2025-02-18, Balance as of period end |
| 2021-12-31 | $301.51M | +52.1% | 2024-02-20, Balance as of period end |
| 2020-12-31 | $198.27M | +97.5% | 2023-03-07, Balance as of period end |
| 2019-12-31 | $100.40M | n/m | 2023-03-07, Balance as of period end |
| 2018-12-31 | -$48.95M | n/m | 2021-03-23, Balance as of period end |
| 2017-12-31 | -$15.74M | n/a | 2020-03-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.02B | -3.4% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $130.34M | +41.5% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $37.21M | -47.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
Compare IDYA, VNDA, AMRN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗